Continual reassessment method for partial ordering

DOI10.1111/J.1541-0420.2011.01560.XzbMATH Open1274.62892OpenAlexW1976972195WikidataQ30423577 ScholiaQ30423577MaRDI QIDQ2893418FDOQ2893418

Authors: Nolan A. Wages, Mark R. Conaway, John O'Quigley 

Publication date: 20 June 2012

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3141101

Recommendations

• Designs for Single- or Multiple-Agent Phase I Trials
• Continual reassessment and related dose-finding designs
• A Curve‐Free Method for Phase I Clinical Trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• On the consistency of the continual reassessment method with multiple toxicity constraints

zbMATH Keywords

dose escalationcontinual reassessment methodmaximum tolerated doseclinical trialdose-finding studiespartial orderingtoxicitydrug combinationphase 1 trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Coherence principles in dose-finding studies
• Design and Analysis of Phase I Clinical Trials
• Confidence interval estimation subject to order restrictions
• Designs for Single- or Multiple-Agent Phase I Trials
• Non-parametric optimal design in dose finding studies
• Dose-finding with two agents in phase I oncology trials
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies
• Two‐Dimensional Dose Finding in Discrete Dose Space
• Continual Reassessment Method: A Likelihood Approach
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents

Cited In (25)

• A Curve‐Free Method for Phase I Clinical Trials
• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
• Continual reassessment method for ordered groups
• A simulation-free approach to assessing the performance of the continual reassessment method
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Improving safety of the continual reassessment method via a modified allocation rule
• Consistency of the when the curve is not monotone and its application to the POCRM
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design
• Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial
• Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
• Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials
• A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering
• Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
• Adaptive clinical trial designs for phase I cancer studies
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• On the consistency of the continual reassessment method with multiple toxicity constraints
• Designs for Single- or Multiple-Agent Phase I Trials
• A phase I dose-finding study based on polychotomous toxicity responses
• A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate

This page was built for publication: Continual reassessment method for partial ordering

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893418)